Tecentriq (atezolizumab) - Risk Of Myocarditis

Tecentriq (atezolizumab), a cancer treatment drug, is being recalled across Canada due to the risk of myocarditis, which is inflammation of the heart muscle. This recall affects patients who have received or may receive this medication. The manufacturer has identified this safety concern and is taking action to address it.

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2018-02-14

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/1fc2bfde-b51a-473f-a56a-1a8e31706998